Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Period	fcf
2015-12-31	-$103.76M
2016-12-31	-$115.79M
2017-12-31	-$100.92M
2018-12-31	-$46.09M
2019-12-31	-$47.13M
2020-12-31	-$41.90M
2021-12-31	-$62.16M
2022-12-31	-$105.56M
2023-12-31	-$109.11M
2024-12-31	-$159.70M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CLDX	$33.62	+3.73%	0.82M
3
4
5

Celldex Therapeutics Inc. (CLDX) Free Cash Flow

Free Cash Flow Data

Get Celldex Therapeutics Inc. Data in Excel

More CLDX Financial Data